All In Biotech

Drug Trial Radar · NCT06531538

A Study to Learn About How a New Pneumococcal Vaccine Works in Children

A PHASE 2, RANDOMIZED, PARTIALLY DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE

Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Jul 30, 2024

Primary completion

Feb 9, 2026

Study completion Feb 9, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety, tolerability and immune effects of a pneumococcal vaccine in toddlers. Participants will take part in this study for approximately 6 or 8 months depending on which group they are assigned to. During this time participants will have 2 clinic visits and 1 phone visit for the 1-Dose group, or 3 clinic visits and 1 phone visit for the 2-Dose group. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during some clinic visits.

Conditions

  • Pneumococcal Disease

Interventions

  • PG4Biological

    Multivalent pneumococcal conjugate vaccine.

  • 20-valent pneumococcal conjugate vaccine (20vPnC)Biological

    20-valent pneumococcal conjugate vaccine (20vPnC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting prespecified local reactions within 7 days after each doseTime frame: 7 days after each dose
  2. Percentage of participants reporting prespecified systemic events within 7 days after each doseTime frame: 7 days after each dose
  3. Percentage of participants reporting Adverse Events (AEs) within 1 month after the last assigned vaccinationTime frame: From signing of ICD to 1 month after last assigned vaccination
  4. Percentage of participants reporting Serious Adverse Events (SAEs) within 6 months after vaccinationTime frame: From signing of ICD to 6 months after last assigned vaccination

Locations

39 sites in 2 countries. Site status is shown where the registry gives one.

  • Emerson Clinical Research Institute

    Washington D.C., District of Columbia

  • Bio-Medical Research LLC

    Miami, Florida

  • Tekton Research, LLC.

    Chamblee, Georgia

  • Javara - Privia Medical Group Georgia - Fayetteville

    Fayetteville, Georgia

  • Rophe Adult and Pediatric Medicine/SKYCRNG

    Union City, Georgia

  • The Iowa Clinic

    Ankeny, Iowa

  • Louisiana State University Health Sciences Shreveport - Fairfield avenue

    Shreveport, Louisiana

  • Louisiana State University Health Sciences Shreveport

    Shreveport, Louisiana

  • Ochsner/LSU Health Ambulatory Care Center

    Shreveport, Louisiana

  • University of Maryland, Baltimore - Institutional Review Board

    Baltimore, Maryland

  • University of Maryland, Baltimore, Center for Vaccine Development and Global Health

    Baltimore, Maryland

  • The Pediatric Center

    Columbia, Maryland

  • Atrium Health - Strive Vaccine Research Clinic

    Charlotte, North Carolina

  • Atrium Health-Myers Park

    Charlotte, North Carolina

  • Duke Vaccine and Trials Unit

    Durham, North Carolina

  • Durham Pediatrics at North Duke Street

    Durham, North Carolina

  • Duke University

    Durham, North Carolina

  • Atrium Health-Matthews

    Matthews, North Carolina

  • Senders Pediatrics

    South Euclid, Ohio

  • Carolina Family Care

    Charleston, South Carolina

  • MUSC Children's Health

    Charleston, South Carolina

  • Carolina Family Care

    Summerville, South Carolina

  • MUSC Children's Health

    Summerville, South Carolina

  • Holston Medical Group

    Kingsport, Tennessee

  • Pediatric Clinical Trials of Tennessee, LLC

    Tullahoma, Tennessee

  • Javara - Privia Medical Group North Texas - Dallas

    Dallas, Texas

  • Oak Cliff Research Company, LLC

    Dallas, Texas

  • Oak Cliff Research Company, LLC

    Dallas, Texas

  • Mercury Clinical Research - Houston

    Houston, Texas

  • DM Clinical Research - Kool Kids Pediatrics

    Houston, Texas

  • Kool Kids Pediatrics

    Houston, Texas

  • Mercury Clinical Research - Sunrise Pediatrics

    Houston, Texas

  • Mercury Clinical Research - Pediatric Associates

    Houston, Texas

  • University of Texas Medical Branch

    League City, Texas

  • Mercury Clinical Research - North Houston Internal Medicine & Pediatric Clinic

    Tomball, Texas

  • Ponce Medical School Foundation Inc.

    Ponce, Puerto Rico

  • BRCR Medical Center - Ponce

    Ponce, Puerto Rico

  • BRCR Global Puerto Rico

    San Juan, Puerto Rico

  • CMRC Headlands, LLC

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.